The transmembrane domains of TNF-related apoptosis-inducing ligand (TRAIL) receptors 1 and 2 co-regulate apoptotic signaling capacity. [PDF]
PLoS ONE, 2012 TNF-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor (TNF) ligand family that exerts its apoptotic activity in human cells by binding to two transmembrane receptors, TRAILR1 and TRAILR2.
Simon Neumann +5 more
doaj +5 more sources
The structure of the death receptor 4–TNF-related apoptosis-inducing ligand (DR4–TRAIL) complex [PDF]
Acta Crystallographica Section F, Structural Biology Communications, 2015 The structure of death receptor 4 (DR4) in complex with TNF-related apoptosis-inducing ligand (TRAIL) has been determined at 3 Å resolution and compared with those of previously determined DR5–TRAIL complexes. Consistent with the high sequence similarity between DR4 and DR5, the overall arrangement of the DR4–TRAIL complex does not differ substantially
Steven Sheriff +2 more
exaly +3 more sources
The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway [PDF]
Oncogene, 2008 Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily and has been shown to induce apoptosis in cancer cells but not normal cells. TRAIL triggers apoptosis through binding to its receptors DR4 and KILLER/DR5.
exaly +3 more sources
PLoS ONE, 2019 High-risk neuroblastoma (NB) is lethal childhood cancer. Published data including ours have reported the anti-proliferative effect of Xanthohumol (XN), a prenylated chalcone, in various cancer types suggesting that XN could be a useful small molecule ...
Samuel Engelsgjerd +4 more
doaj +4 more sources
TRAIL and its receptors in cardiac diseases
Frontiers in Physiology, 2023 Cardiovascular disease is a leading cause of death worldwide. Loss of cardiomyocytes that occurs during many types of damage to the heart such as ischemic injury and stress caused by pressure overload, diminishes cardiac function due to their limited ...
Laurel A. Grisanti
doaj +1 more source
Behind the Adaptive and Resistance Mechanisms of Cancer Stem Cells to TRAIL
Pharmaceutics, 2021 Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also known as Apo-2 ligand (Apo2L), is a member of the TNF cytokine superfamily. TRAIL has been widely studied as a novel strategy for tumor elimination, as cancer cells overexpress ...
Adriana G. Quiroz-Reyes +5 more
doaj +1 more source
Scientific Reports, 2021 In triple-negative breast cancer (TNBC), the tumor microenvironment is associated with increased proliferation, suppressing apoptotic mechanisms, an altered immune response, and drug resistance.
Patricia Mendonca +3 more
doaj +1 more source
Overcoming TRAIL Resistance for Glioblastoma Treatment
Biomolecules, 2021 The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) shows a promising therapeutic potential in cancer treatment as it exclusively causes apoptosis in a broad spectrum of cancer cells through triggering the extrinsic apoptosis ...
Longfei Deng +3 more
doaj +1 more source
Inhibition of the TRAIL death receptor by CMV reveals its importance in NK cell-mediated antiviral defense. [PDF]
PLoS Pathogens, 2014 TNF-related apoptosis inducing ligand (TRAIL) death receptors (DR) regulate apoptosis and inflammation, but their role in antiviral defense is poorly understood.
Shilpi Verma +5 more
doaj +1 more source
TRAF-6 dependent signaling pathway is essential for TNF-related apoptosis-inducing ligand (TRAIL) induces osteoclast differentiation. [PDF]
PLoS ONE, 2012 Human osteoclast formation from mononuclear phagocyte precursors involves interactions between tumor necrosis factor (TNF) ligand superfamily members and their receptors. Recent evidence indicates that in addition to triggering apoptosis, the TNF-related
Men-Luh Yen +4 more
doaj +1 more source